<DOC>
	<DOC>NCT01968915</DOC>
	<brief_summary>This study will evaluate safety and tolerability to estimate the maximum tolerated dose and/or recommended dose of oral LCL161 in Japanese patients with advanced solid tumors.</brief_summary>
	<brief_title>Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criteria: 1. Patients with a histologically or cytologically confirmed diagnosis of a solid tumor for which no further effective standard treatment is available. 2. ECOG performance status 01. 3. Patients must have recovered from all toxicities related to their previous treatment. Exclusion criteria: 1. Unresolved nausea, vomiting, diarrhea or peripheral neuropathy CTCAE grade &gt;1. 2. History of or current interstitial lung disease or autoimmune disease. 3. History of or current impaired cardiac function or clinically significant cardiac diseases. 4. Women of childbearing potential, unless they are using highly effective methods of contraception. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>LCL161, Paclitaxel, Japanese patient, Neoplasms</keyword>
</DOC>